KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in KALA BIO, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 85
- −21 vs. Q3 2021
- Shares held
- 25.5M
- −4.80M (−15.8%) vs. Q3 2021
- Total value
- $30.9M
- −$48.6M (−61.2%) vs. Q3 2021
- New holders
- 16
- 18 more added
- Sold out
- 37
- 34 more reduced
2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KALA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $1.21M |
| Q1 2026 | 30 | $294.0K |
| Q4 2025 | 32 | $1.58M |
| Q3 2025 | 24 | $2.69M |
| Q2 2025 | 30 | $17.3M |
| Q1 2025 | 29 | $23.7M |
| Q4 2024 | 33 | $24.0M |
| Q3 2024 | 27 | $12.1M |
| Q2 2024 | 29 | $14.8M |
| Q1 2024 | 29 | $4.88M |
| Q4 2023 | 25 | $3.68M |
| Q3 2023 | 26 | $4.57M |
| Q2 2023 | 30 | $5.56M |
| Q1 2023 | 26 | $4.81M |
| Q4 2022 | 30 | $12.8M |
| Q3 2022 | 56 | $1.36M |
| Q2 2022 | 70 | $2.27M |
| Q1 2022 | 88 | $33.7M |
| Q4 2021 | 85 | $30.9M |
| Q3 2021 | 108 | $79.5M |
| Q2 2021 | 107 | $171.3M |
| Q1 2021 | 118 | $248.9M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding KALA BIO, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −25,375−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −23,634−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Chicago Partners Investment Group LLC | 0 | $0 | 0.00% | −26,499−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −20,240−100.0% | Sold out |
| Csenge Advisory Group | 0 | $0 | 0.00% | −19,250−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −19,498−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −18,454−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −14,216−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −12,231−100.0% | Sold out |
| Arizona State Retirement System | 0 | $0 | 0.00% | −11,445−100.0% | Sold out |
| FineMark National Bank & Trust | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −9,750−100.0% | Sold out |
| MCF Advisors LLC | 0 | $0 | 0.00% | −8,448−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −7,294−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −6,838−100.0% | Sold out |
| Great West Life Assurance Co | 0 | $0 | 0.00% | −2,751−100.0% | Sold out |
| Jacobi Capital Management LLC | 0 | $0 | 0.00% | −2,325−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −1,490−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −361−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −166−100.0% | Sold out |
| Symons Capital Management Inc | – | – | – | – | Not filed |
| Berman Capital Advisors, LLC | – | – | – | – | Not filed |